Literature DB >> 17252015

A phase II study of temozolomide therapy for poor-risk patients aged >or=60 years with acute myeloid leukemia: low levels of MGMT predict for response.

J M Brandwein, L Yang, A D Schimmer, A C Schuh, V Gupta, R A Wells, S M H Alibhai, W Xu, M D Minden.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17252015     DOI： 10.1038/sj.leu.2404545

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  5 in total

1.  Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: association with a particular immunophenotype of blast cells.

Authors:  Nada Kraguljac Kurtović; Milena Krajnović; Andrija Bogdanović; Nada Suvajdžić; Jelica Jovanović; Bogomir Dimitrijević; Milica Colović; Koviljka Krtolica
Journal:  Med Oncol       Date:  2012-07-07       Impact factor: 3.064

2.  Organized Pneumonia Secondary to Increasing Doses of Temozolomide.

Authors:  Pedro J Marcos; Angélica Consuegra Vanegas; María Matachana Martínez; Lourdes Cordero Lorenzana; Iria Vidal García; Carmen Montero Martínez
Journal:  Cureus       Date:  2015-09-09

3.  Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus.

Authors:  Joseph M Brandwein; Michelle Geddes; Jeannine Kassis; Andrea K Kew; Brian Leber; Thomas Nevill; Mitchell Sabloff; Irwindeep Sandhu; Andre C Schuh; John M Storring; John Ashkenas
Journal:  Am J Blood Res       Date:  2013-05-05

4.  A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.

Authors:  Ivana Gojo; Jan H Beumer; Keith W Pratz; Michael A McDevitt; Maria R Baer; Amanda L Blackford; B Douglas Smith; Steven D Gore; Hetty E Carraway; Margaret M Showel; Mark J Levis; Amy E Dezern; Douglas E Gladstone; Jiuping Jay Ji; Lihua Wang; Robert J Kinders; Marie Pouquet; Ismail Ali-Walbi; Michelle A Rudek; Weijie Poh; James G Herman; Larry M Karnitz; Scott H Kaufmann; Alice Chen; Judith E Karp
Journal:  Clin Cancer Res       Date:  2016-08-08       Impact factor: 12.531

5.  Temozolomide and cisplatin in relapsed/refractory acute leukemia.

Authors:  Karen Seiter; Sreedhar Katragadda; Doris Ponce; Muhammad Rasul; Nasir Ahmed
Journal:  J Hematol Oncol       Date:  2009-05-22       Impact factor: 17.388
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.